Source Mutations/Fusions Platform Company 1 *EGFR, *T790M,*ALK, ROS1, ddPCR RET, *KRAS, BRAF Company 2 ALK, hENT1, MET, PD-L1, NGS, IHC PTEN, R0S1, T0P01, TP, TRKpan, TUBB3
Company 3 *EGFR, *T790M, *ALK rtPCR w/ NGS Company 4 *EGFR, T790M, ALK, R0S1, rtPCR RET, KRAS, BRAF, MET, HER2 Company 5 EGFR1, EGFR T790M, ALK1, ddPCR R0S11, KRAS1, PD-L11 Company 6 *EGFR, *T790M, KRAS, BRAF ddPCR w/ NGS Source Performance Sensitivity Specificity Company 1 91% (1) 100% (1) Company 2 N/A (2) N/A (2) Company 3 EGFR: 86%3 EGFR: NA T790M: 64.
RT PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3
and RRM1 in NSCLC.
sup] confirmed ovarian cancer patients with low expression of targets (TUBB3
) of antimicrotubular drugs had obviously longer survival period than patients with high expression of TUBB3
by TaqMan probe, suggesting miR-200c can increase the sensitivity of ovarian cancer tissues to chemotherapy drug taxol via target regulation on TUBB3
001 disease FKBP4, FLNA, KRT14, KRT16, KRT5, KRT6A, PSMB1, S100A8, S100A9, SERPINB13, SFN, TPM1, TPM3, TUBB, TUBB3
, TUBB4A, VCL Cell death and ANXA2, CALM1, 35 < .
Objective: We aimed to analyze the expression of ERCC1 RRM1 and TUBB3 in 305 patients with advanced non-small cell lung cancer (NSCLC) and investigate whether these genes can be used as biomarkers for predicting tumor response and clinical outcome.
cDNA of ERCC1 RRM1 and TUBB3 was isolated by a fluorescence-based real-time detection method.
The median levels of ERCC1 RRM1 and TUBB3 mRNA were 0.
However few studies have investigated the effect of ERCC1 RRM1 and AY-tubulin III(TUBB3) expression on the clinical outcome of NSCLC or the association between ERCC1 RRM1 and TUBB3 and clinical characteristics.
En az iki gende heterozigot mutasyonlar tespit edilmistir: TUBB3 (KEOKF 3A) ve KIF21A geni (KEOKF 3B).
Human TUBB3 mutations perturb microtubule dynamics, kinesin interactions, and axon guidance.
Em 2006 os mesmos autores reafirmaram a expressao de marcadores de pluricelularidade Oct -4 e NANOG-, e verificaram a expressao de diversos marcadores neurogenicos como NES, TUBB3
, NEFH, NEUNA60 GALC E GFAP antes e depois da inducao da diferenciacao neurogenica (31).
mRNA Expression and Clinical Significance of ERCC1 BRCA1 RRM1 TYMS and TUBB3
in Postoperative Patients with Non-Small Cell Lung Cancer.